Subscribe to RSS
DOI: 10.1055/s-0041-1735558
Treatment and Prognosis of Inflammatory Pseudotumor of the Skull Base
Abstract
Background Inflammatory pseudotumor (IPT) of the skull base is a rare, locally destructive lesion managed with a variety of treatments. We explore the impact of treatment on outcome and assess the prognosis of IPT.
Methods This is a retrospective review of IPT of the skull base at a tertiary academic medical center. The primary outcome was radiographic progression after treatment. Outcome versus tumor location was also examined and a prognostic model was developed using a logistic regression.
Results The demographics of 21 patients with IPT are reported. Treatment consisted of corticosteroids (in 80.1% of patients), disease modifying antirheumatic drugs (DMARDs; 33.3%), surgical resection (28.6%), radiation (23.8%), antibiotics (14.3%), chemotherapy (rituximab; 9.5%), and antivirals (4.8%). At 50.7 months, 50.8% had radiographic progression. Local therapy trended toward having a better response than systemic therapy (p = 0.60). IPT of the orbit required 2.4 treatment modalities, compared with 2.0 for pharyngeal IPT, and 1.3 for posterior skull base masses (p = 0.14). A total of 75% orbital IPT underwent radiographic progression, compared with 71% of pharyngeal IPT and 50% of posterior skull base masses (p = 0.62). Sixteen patients were used to create the logistic model of radiographic progression. The Cox–Snell R 2 was 0.71 (p = 0.03). No individual variables were statistically significant.
Conclusion To our knowledge, this is among the largest sample of cases describing the presentation, treatment, and prognosis of IPT of the skull base. Our data suggest that there may be an improved response with local therapy over systemic therapy and better prognosis among posterolateral skull base masses.
Keywords
Inflammatory pseudotumor - skull base - plasma cell granuloma - inflammatory myofibroblastoma - fibroinflammatory pseudotumorPublication History
Received: 12 April 2021
Accepted: 25 July 2021
Article published online:
10 September 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Brunn H. Two interesting benign lung tumors of contradictory histopathology. J Thorac Surg 1939; 9: 119-131
- 2 Narla LD, Newman B, Spottswood SS, Narla S, Kolli R. Inflammatory pseudotumor. Radiographics 2003; 23 (03) 719-729
- 3 Umiker WO, Iverson L. Postinflammatory tumors of the lung; report of four cases simulating xanthoma, fibroma, or plasma cell tumor. J Thorac Surg 1954; 28 (01) 55-63
- 4 Magro G. Differential diagnosis of benign spindle cell lesions. Surg Pathol Clin 2018; 11 (01) 91-121
- 5 Lai LM, McCarville MB, Kirby P. et al. Shedding light on inflammatory pseudotumor in children: spotlight on inflammatory myofibroblastic tumor. Pediatr Radiol 2015; 45 (12) 1738-1752
- 6 Patnana M, Sevrukov AB, Elsayes KM, Viswanathan C, Lubner M, Menias CO. Inflammatory pseudotumor: the great mimicker. AJR Am J Roentgenol 2012; 198 (03) W217-27
- 7 Das Narla L, Siddiqi NH, Hingsbergen EA. Inflammatory pseudotumor of the right atrium. Pediatr Radiol 2001; 31 (05) 351-353
- 8 Kovach SJ, Fischer AC, Katzman PJ. et al. Inflammatory myofibroblastic tumors. J Surg Oncol 2006; 94 (05) 385-391
- 9 Zhang Z, Fu W, Wang M. et al. IgG4-related inflammatory pseudotumor of the brain parenchyma: a case report and literature review. Acta Neurol Belg 2018; 118 (04) 617-627
- 10 Inada T, Yano T, Shima S. et al. Inflammatory pseudotumor of the spleen. Intern Med 1992; 31 (07) 941-945
- 11 Teoh JY, Chan NH, Cheung HY, Hou SS, Ng CF. Inflammatory myofibroblastic tumors of the urinary bladder: a systematic review. Urology 2014; 84 (03) 503-508
- 12 Sadeeq KJ, Yaqo RT, Mohammed AA. Inflammatory pseudotumor of the tunica albuginea and the tunica vaginalis: case-report. Urol Case Rep 2019; 26: 100954
- 13 Hamzaoui L, Medhioub M, Mahmoudi M, Chelbi E, Bouzaidi K, Msadak Azouz M. Inflammatory pseudotumor of the liver. Presse Med 2016; 45 (09) 804-807
- 14 Park SB, Lee JH, Weon YC. Imaging findings of head and neck inflammatory pseudotumor. AJR Am J Roentgenol 2009; 193 (04) 1180-1186
- 15 Kansara S, Bell D, Johnson J, Zafereo M. Head and neck inflammatory pseudotumor: case series and review of the literature. Neuroradiol J 2016; 29 (06) 440-446
- 16 Ginat DT, Bokhari A, Bhatt S, Dogra V. Inflammatory pseudotumors of the head and neck in pathology-proven cases. J Neuroradiol 2012; 39 (02) 110-115
- 17 Desai SV, Spinazzi EF, Fang CH. et al. Sinonasal and ventral skull base inflammatory pseudotumor: a systematic review. Laryngoscope 2015; 125 (04) 813-821
- 18 Marinelli JP, Marvisi C, Vaglio A. et al. Manifestations of skull base IgG4-related disease: a multi-institutional study. Laryngoscope 2020; 130 (11) 2574-2580
- 19 Korlepara R, Guttikonda VR, Madala J, Taneeru S. Inflammatory myofibroblastic tumor of mandible: a rare case report and review of literature. J Oral Maxillofac Pathol 2017; 21 (01) 136-139
- 20 Spinazzi EF, Desai SV, Fang CH. et al. Lateral skull base Inflammatory pseudotumor: a systematic review. Laryngoscope 2015; 125 (11) 2593-2600
- 21 Garg V, Temin N, Hildenbrand P, Silverman M, Catalano PJ. Inflammatory pseudotumor of the skull base. Otolaryngol Head Neck Surg 2010; 142 (01) 129-131
- 22 Alyono JC, Shi Y, Berry GJ. et al. Inflammatory pseudotumors of the skull base: meta-analysis. Otol Neurotol 2015; 36 (08) 1432-1438
- 23 Lee DK, Cho YS, Hong SH, Chung WH, Ahn YC. Inflammatory pseudotumor involving the skull base: response to steroid and radiation therapy. Otolaryngol Head Neck Surg 2006; 135 (01) 144-148
- 24 Ortlip TE, Drake VE, Raghavan P. et al. Inflammatory pseudotumor of the temporal bone: a case series. Otol Neurotol 2017; 38 (07) 1024-1031
- 25 Butrynski JE, D'Adamo DR, Hornick JL. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363 (18) 1727-1733
- 26 Garcia BA, Tinsley S, Schellenberger T, Bobustuc GC. Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab. Med Oncol 2012; 29 (04) 2452-2455